GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line
Executive Summary
UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.
You may also be interested in...
US OTC Switch Drought Ends: FDA Approves GSK Arthritis Gel, Alcon Allergy Eye Drops
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.
GSK Unveils Two-Year Plan For Consumer Split
GSK preparing to seize “a major opportunity to create a new leader in consumer h
GSK And Pfizer Assemble Consumer Healthcare Leadership Team As JV Closes
Under Brian McNamara’s leadership, GSK Consumer Healthcare has begun to assemble a management team that combines talent from both GSK and Pfizer.